SARS-CoV-2 and ACE2: The biology and clinical data settling the ARB and ACEI controversy

Background: SARS-CoV-2 enters cells by binding of its spike protein to angiotensin-converting enzyme 2 (ACE2). Angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin II receptor blockers (ARBs) have been reported to increase ACE2 expression in animal models, and worse outcomes are reported...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Mina K. Chung, Sadashiva Karnik, Joshua Saef, Cornelia Bergmann, John Barnard, Michael M. Lederman, John Tilton, Feixiong Cheng, Clifford V. Harding, James B. Young, Neil Mehta, Scott J. Cameron, Keith R. McCrae, Alvin H. Schmaier, Jonathan D. Smith, Ankur Kalra, Surafel K. Gebreselassie, George Thomas, Edward S. Hawkins, Lars G. Svensson
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2020-08-01
Colecção:EBioMedicine
Assuntos:
COVID-19
ACE2
ACE inhibitors
ARBs
SARS-CoV-2
Kallikrein-kinin system
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S2352396420302826
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados